Phase II trial of S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer

British Journal of Cancer

Volumn 101, Issue 2, 2009, Pages 225-231

  Ohyanagi, F ^a   Yamamoto, N ^b   Horiike, A ^a   Harada, H ^b   Kozuka, T ^a   Murakami, H ^b   Gomi, K ^a   Takahashi, T ^b   Morota, M ^a   Nishimura, T ^a   Endo, M ^b   Nakamura, Y ^b   Tsuya, A ^b   Horai, T ^a   Nishio, M ^a  

^a CANCER INSTITUTE HOSPITAL   (Japan)

^b SHIZUOKA CANCER CENTER   (Japan)

Author keywords

Chemotherapy; Cisplatin; Non small cell lung cancer; Radiotherapy; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN; ANTINEOPLASTIC AGENT; OXONIC ACID; S 1 (COMBINATION); TEGAFUR;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TOXICITY; BRAIN HEMORRHAGE; CANCER LOCALIZATION; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG TOLERABILITY; ESOPHAGITIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HISTOPATHOLOGY; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; SIDE EFFECT; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT RESPONSE; DISEASE FREE SURVIVAL; DRUG COMBINATION; LUNG TUMOR; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DRUG COMBINATIONS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; OXONIC ACID; SURVIVAL RATE; TEGAFUR;

EID: 67650594774     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605152     Document Type: Article

References (37)

1. Bedano PM, Neubauer M, Ansari R, Govindan R, Einhorn LH, Bruetman D, White A, Breen T, Juliar B, Hanna N (2006) Phase III study of cisplatin (P) plus etoposide (E) with concurrent chest radiation (XRT) followed by docetaxel (D) vs observation in patients (pts) with stage III non-small cell lung cancer (NSCLC): An interim toxicity analysis of consolidation therapy. J Clin Oncol 2006 ASCO Annu Meet Proc 24 (20 June Suppl): Part I; abstract no. 7043
2. Belani CP, Choy H, Bonomi P, Scott C, Travis P, Haluschak J, Curran Jr WJ (2005) Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol 23: 5883-5891
3. Brade AM, Bezjak A, MacRae R, Laurie SA, Pond GR, Wang L, Dick C, Afinec A, Iscoe N, Shepherd FA (2008) A phase I study of concurrent pemetrexed (P)/cisplatin (C)/radiation (RT) for unresectable stage IIIA/B non-small cell lung cancer (NSCLC). J Clin Oncol 26 (20 May Suppl): abstract no. 7550
4. Bunn Jr PA, Kelly K (1998) New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res 4: 1087-1100
5. Chikamori K, Kishino D, Takigawa N, Hotta K, Nogami N, Kamei H, Kuyama S, Gemba K, Takemoto M, Kanazawa S, Ueoka H, Segawa Y, Takata S, Tabata M, Kiura K, Tanimoto M (2009) A phase I study of combination S-1 plus cisplatin chemotherapy with concurrent thoracic radiation for locally advanced non-small cell lung cancer. Lung Cancer 65: 74-79
6. Choy H, Akerley W, Safran H, Graziano S, Chung C, Williams T, Cole B, Kennedy T (1998) Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. J Clin Oncol 16: 3316-3322
7. Curran WJ, Scott CB, Langer CJ, Komaki R, Lee JS, Hauser S, Movsas B, Wasserman T, Sause W, Cox JD (2003) Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 9410. Proc Am Soc Clin Oncol 22; abstract no. 2499a
8. Endo M, Yamamoto N, Sakai H, Kubota K, Kunitoh H, Nakagawa K, Takeda K, Ichinose Y (2006) Phase II study of 3-weekly S-1 plus cisplatin in patients with advanced non-small cell lung cancer (NSCLC). Proc ESMO; abstract 752P
9. Fournel P, Robinet G, Thomas P, Souquet PJ, Lena H, Vergnenegre A, Delhoume JY, Le Treut J, Silvani JA, Dansin E, Bozonnat MC, Daures JP, Mornex F, Perol M (2005) Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study. J Clin Oncol 23: 5910-5917
10. Fukushima M, Satake H, Uchida J, Shimamoto Y, Kato T, Takechi T, Okabe H, Fujioka A, Nakano K, Ohshimo H, Takeda S, Shirasaka T (1998) Preclinical antitumor efficacy of S-1: a new oral formulation of 5-fluorouracil on human tumor xenografts. Int J Oncol 13: 693-698
11. Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, Katagami N, Ariyoshi Y (1999) Phase III study of concurrent vs sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17: 2692-2699
12. Gandara DR, Chansky K, Albain KS, Leigh BR, Gaspar LE, Lara Jr PN, Burris H, Gumerlock P, Kuebler JP, Bearden III JD, Crowley J, Livingston R (2003) Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol 21: 2004-2010
13. Harada K, Kawaguchi S, Supriatno, Onoue T, Yoshida H, Sato M (2004) Combined effects of the oral fluoropyrimidine anticancer agent, S-1 and radiation on human oral cancer cells. Oral Oncol 40: 713-719
14. Hoff PM, Saad ED, Ajani JA, Lassere Y, Wenske C, Medgyesy D, Dwivedy S, Russo M, Pazdur R (2003) Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors. Clin Cancer Res 9: 134-142
15. Hoffman PC, Mauer AM, Vokes EE (2000) Lung cancer. Lancet 355: 479-485
16. Ichinose Y, Yoshimori K, Sakai H, Nakai Y, Sugiura T, Kawahara M, Niitani H (2004) S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: a multi-institutional phase II trial. Clin Cancer Res 10: 7860-7864
17. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer statistics 2007. CA Cancer J Clin 57: 43-66
18. Johnson DH (1999) Treatment strategies for metastatic non small-cell lung cancer. Clin Lung Cancer 1: 34-41
19. Kaira K, Sunaga N, Yanagitani N, Kawata T, Utsugi M, Shimizu K, Ebara T, Kawamura H, Nonaka T, Ishikawa H, Sakurai H, Suga T, Hara K, Hisada T, Ishizuka T, Nakano T, Mori M (2008) Phase I study of oral S-1 plus cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (in press)
20. Kawahara M, Furuse K, Segawa Y, Yoshimori K, Matsui K, Kudoh S, Hasegawa K, Niitani H (2001) Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer 85: 939-943
21. Kiura K, Takigawa N, Segawa Y, Kamei H, Takemoto M, Tabata M, Ueoka H, Hiraki S, Matsuo K, Tanimoto M (OLCSG) (2008) Randomized phase III trial of docetaxel and cisplatin combination chemotherapy vs mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiation therapy for locally advanced non-small-cell lung cancer: OLCSG 0007. J Clin Oncol 26 (20 May Suppl): abstract no. 7515
22. Kiura K, Ueoka H, Segawa Y, Tabata M, Kamei H, Takigawa N, Hiraki S, Watanabe Y, Bessho A, Eguchi K, Okimoto N, Harita S, Takemoto M, Hiraki Y, Harada M, Tanimoto M (2003) Phase I/II study of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small-cell lung cancer. Br J Cancer 89: 795-802
23. Le Chevalier T, Arriagada R, Quoix E, Ruffie P, Martin M, Tarayre M, Lacombe-Terrier MJ, Douillard JY, Laplanche A (1991) Radiotherapy alone vs combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 83: 417-423
24. Non-Small Cell Lung Cancer Collaborative-Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 311: 899-909
25. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26: 3543-3551
26. Schaake-Koning C, van den Bogaert W, Dalesio O, Festen J, Hoogenhout J, van Houtte P, Kirkpatrick A, Koolen M, Maat B, Nijs A (1992) Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 326: 524-530
27. Schultz RM, Patel VF, Worzalla JF, Shih C (1999) Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514. Anticancer Res 19: 437-443
28. Shirasaka T, Yamamitsu S, Tsuji A, Taguchi T (2000) Conceptual changes in cancer chemotherapy: from an oral fluoropyrimidine prodrug, UFT, to a novel oral fluoropyrimidine prodrug, S-1, and low-dose FP therapy in Japan. Invest New Drugs 18: 315-329
29. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10: 1-10
30. Socinski MA, Blackstock AW, Bogart JA, Wang X, Munley M, Rosenman J, Gu L, Masters GA, Ungaro P, Sleeper A, Green M, Miller AA, Vokes EE (2008) Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. J Clin Oncol 26: 2457-2463
31. Taylor EC, Kuhnt D, Shih C, Rinzel SM, Grindey GB, Barredo J, Jannatipour M, Moran RG (1992) A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d] pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase. J Med Chem 35: 4450-4454
32. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216
33. van Groeningen CJ, Peters GJ, Schornagel JH, Gall H, Noordhuis P, de Vries MJ, Turner SL, Swart MS, Pinedo HM, Hanauske AR, Giaccone G (2000) Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. J Clin Oncol 18: 2772-2779
34. van Meerbeeck JP (2001) Staging of non-small cell lung cancer: consensus, controversies and challenges. Lung Cancer 34(Suppl 2): S95-S107
35. Vokes EE, Herndon II JE, Crawford J, Leopold KA, Perry MC, Miller AA, Green MR (2002) Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol 20: 4191-4198
36. Yamada Y, Hamaguchi T, Goto M, Muro K, Matsumura Y, Shimada Y, Shirao K, Nagayama S (2003) Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydro-pyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil. Br J Cancer 89: 816-820
37. Zatloukal P, Petruzelka L, Zemanova M, Havel L, Janku F, Judas L, Kubik A, Krepela E, Fiala P, Pecen L (2004) Concurrent vs sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 46: 87-98